Skip to main content
. 2021 Dec 23;7(1):100336. doi: 10.1016/j.esmoop.2021.100336

Figure 1.

Figure 1

Diagram representing our patient population available for analysis.

Patients who received both chemotherapy and immunotherapy in the metastatic/unresectable setting (N = 18) are noted. A total of 15 out of these 18 patients were used to calculate the progression-free survival ratio (PFS2/PFS1) as they received chemotherapy before immunotherapy.